Triaziquone

Triaziquone

SCHEMBL5800741

NCO.O=C1C=C(N2CC2)C(=O)C(N2CC2)=C1N1CC1

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNMT1 P26358 1/20 0.41
HTT P42858 2/20 0.39
TP53 P04637 1/20 0.39
MAPT P10636 1/20 0.39
STAT3 P40763 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NSD2 O96028 3/20 0.34
APAF1 O14727 2/20 0.34
TDP2 O95551 2/20 0.34
HKDC1 Q2TB90 2/20 0.34
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
HIF1A Q16665 1/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
GALK1 P51570 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Triaziquone SCHEMBL11791565 0.96 DNMT1 (0.39) DNMT1HTTTP53MAPTSTAT3
Triaziquone SCHEMBL1961248 0.93 DNMT1 (0.39) DNMT1HTTTP53MAPTSTAT3
Triaziquone SCHEMBL8585531 0.92 HTT (0.37) DNMT1HTTTP53MAPTSTAT3
Triaziquone SCHEMBL7616616 0.91 DNMT1 (0.38) DNMT1HTTTP53MAPTSTAT3
Triaziquone SCHEMBL3191414 0.91 DNMT1 (0.38) DNMT1HTTTP53MAPTSTAT3
Triaziquone SCHEMBL610295 0.91 DNMT1 (0.42) DNMT1HTTTP53MAPTSTAT3
Triaziquone SCHEMBL7996887 0.90 DNMT1 (0.37) DNMT1HTTTP53MAPTSTAT3
Triaziquone SCHEMBL3505984 0.90 DNMT1 (0.37) DNMT1HTTTP53MAPTSTAT3
Triaziquone SCHEMBL11350903 0.89 HTT (0.42) DNMT1HTTTP53MAPTSTAT3
Triaziquone SCHEMBL242425 0.89 DNMT1 (0.41) DNMT1HTTTP53MAPTSTAT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2006079364-A1 SPECIFIC AND MILD PEPTIDE OR AMIDE BOND CLEAVAGE STICHTING VOOR DE TECHNISCHE WETENSCHAPPEN (NL) 2006-08-03 WO disclosed
US-20030092767-A1 Combination therapy for the treatment of inflammatory and respiratory diseases ELI LILLY AND COMPANY 2003-05-15 US disclosed
US-20020198138-A1 Combination therapy for the treatment of inflammatory and respiratory diseases ELI LILLY AND COMPANY 2002-12-26 US disclosed
EP-0754948-B1 Method for measuring the amount of constituent contained in specific lipotrotein WAKO PURE CHEM IND LTD (JP) 2001-10-17 EP disclosed
US-5962439-A CARDIOVASCULAR DISORDER ONO PHARMACEUTICAL CO., LTD. (JP) 1999-10-05 US disclosed
US-5849919-A Fused benzeneoxyacetic acid derivatives which have PGI2 receptor anonist activity ONO PHARMACEUTICAL CO., LTD. (JP) 1998-12-15 US disclosed
EP-0548949-B1 Fused benzeneoxyacetic acid derivatives ONO PHARMACEUTICAL CO (JP) 1997-09-17 EP disclosed
US-5596009-A TREATMENT OF THROMBOSIS, ATHERIOSCLEROSIS, ANTIISCHEMIC AGENTS, ANTIULCER AGENTS OR HYPOTENSIVE AGENTS ONO PHARMACEUTICAL CO., LTD. (JP) 1997-01-21 US disclosed
US-5589496-A Fused benzeneoxyacetic acid derivatives which have PGI2 receptor agonist activity ONO PHARMACEUTICAL CO., LTD. (JP) 1996-12-31 US disclosed
EP-0578847-B1 Fused benzeneoxyacetic acid derivatives and their use as PG12 antagonists ONO PHARMACEUTICAL CO (JP) 1996-10-09 EP disclosed
US-5336681-A Elastase inhibitors ONO PHARMACEUTICAL CO., LTD. (JP) 1994-08-09 US disclosed
EP-0578847-A1 Fused benzeneoxyacetic acid derivatives and their use as PG12 antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 1994-01-19 EP disclosed
EP-0347168-B1 DERIVATIVES OF P-SUBSTITUTED PHENYL ESTER OF PIVALIC ACID ONO PHARMACEUTICAL CO (JP) 1993-09-01 EP disclosed
EP-0548949-A2 Fused benzeneoxyacetic acid derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 1993-06-30 EP disclosed
EP-0542203-A2 Fused benzeneoxyacetic acid derivatives as PGl2 receptor agonists ONO PHARMACEUTICAL CO., LTD. (JP) 1993-05-19 EP disclosed
US-5017610-A Elastase inhibitor ONO PHARMACEUTICAL CO., LTD. (JP) 1991-05-21 US disclosed
EP-0347168-A1 Derivatives of p-substituted phenyl ester of pivalic acid ONO PHARMACEUTICAL CO., LTD. (JP) 1989-12-20 EP disclosed
EP-0013617-B1 PENICILLIN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING CERTAIN OF THESE COMPOUNDS BEECHAM GROUP PLC (GB) 1984-07-04 EP disclosed
US-4347182-A Preparation of penicillanic acid derivatives BEECHAM GROUP LIMITED (GB) 1982-08-31 US disclosed
EP-0013617-A1 Penicillin derivatives, process for their preparation and pharmaceutical compositions containing certain of these compounds BEECHAM GROUP PLC (GB) 1980-07-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198138-A1 Combination therapy for the treatment of inflammatory and respiratory diseases SERPINB1, ELANE, MPO DNMT1 4779/4885HTT 2473/4885TP53 3425/4885
US-20030092767-A1 Combination therapy for the treatment of inflammatory and respiratory diseases SERPINB1, ELANE, SPINT2 DNMT1 4450/4885HTT 3892/4885TP53 4537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.